OSLO, Norway , June 8, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO) , the Bladder Cancer Company, and Artera, a leading precision medicine company, announce launch of a joint research initiative....
OSLO, Norway , June 4, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO) , a leader in bladder cancer diagnostics, today announced the signing and successful completion of its acquisition of Vesica...
OSLO, Norway , May 18, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of two Photocure-supported abstracts at the American Urological Association...
OSLO, Norway , May 7, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix ® /Cysview ® revenues of NOK 139.0 million in the first quarter of 2026 (Q1 2025: NOK...
OSLO, Norway , May 4, 2026 /PRNewswire/ --Â Photocure ASA (OSE: PHO) , the Bladder Cancer Company, announces the publication in 'The Journal of Medical Economics' of a novel health economics...
OSLO, Norway , April 13, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO) today announced that the U.S. Food and Drug Administration (FDA) has communicated to Photocure that it plans to issue...
OSLO, Norway , March 16, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two "trial in progress" presentations at the 2026 European Association of Urology congress...
OSLO, Norway , March 3, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today...
OSLO, Norway , Feb. 18, 2026 /PRNewswire/ --  Photocure ASA (OSE: PHO) today reported Hexvix ® /Cysview ®  revenues of NOK 135.1 million in the fourth quarter of 2025 (Q4 2024:...
As Microsoft unveils a new community-friendly face on its data center land grab, our top technical strategist explains the ‘Mad Max’-style investing thesis bubbling up under the surface.